Matthew Hitron
Impact in
- Toxicology top 5%
- Bioactive Compounds and Antitumor Agents
-
- Cancer Cells and Metastasis
- Cytokine Signaling Pathways and Interactions
- Colorectal Cancer Treatments and Studies
Papers in
- Toxicology 16
- Bioactive Compounds and Antitumor Agents 16
- Oncology 12
- Cancer Treatment and Pharmacology 5
- Colorectal Cancer Treatments and Studies 5
- HER2/EGFR in Cancer Research 4
- Co-authors
- Chiang Li (17 shared papers)William J. Edenfield (11 shared papers)Youzhi Li (8 shared papers)Derek J. Jonker (6 shared papers)Joe Stephenson (4 shared papers)Wěi Li (7 shared papers)Adrian Langleben (8 shared papers)David Leggett (3 shared papers)
- Journals
- Journal of Clinical Oncology (21 papers)Blood (2 papers)Annals of Oncology (2 papers)Pharmacology Research & Perspectives (1 paper)Cancers (1 paper)
- Partner nations
- United StatesCanadaJapan
In The Last Decade
Matthew Hitron
30 papers receiving 228 citations
Peers
Comparison fields: 5 of 33
- Toxicology 60
- Oncology 146
- Pathology and Forensic Medicine 39
- Pharmacology 16
- Cancer Research 21
Countries citing papers authored by Matthew Hitron
This map shows the geographic impact of Matthew Hitron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Hitron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Hitron more than expected).
Fields of papers citing papers by Matthew Hitron
This network shows the impact of papers produced by Matthew Hitron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Hitron. The network helps show where Matthew Hitron may publish in the future.
Co-authors
The 25 scholars most cited alongside Matthew Hitron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 24 | |
| 2 | 2013 | 23 | |
| 3 | 2022 | 22 | |
| 4 | 2014 | 17 | |
| 5 | 2014 | 16 | |
| 6 | 2016 | 13 | |
| 7 | 2014 | 13 | |
| 8 | 2017 | 10 | |
| 9 | 2016 | 9 | |
| 10 | 2016 | 9 | |
| 11 | 2017 | 7 | |
| 12 | 2017 | 7 | |
| 13 | 2016 | 7 | |
| 14 | 2021 | 6 | |
| 15 | 2016 | 5 | |
| 16 | 2018 | 5 | |
| 17 | 2017 | 4 | |
| 18 | 2017 | 4 | |
| 19 | 2017 | 4 | |
| 20 | 2022 | 4 |
About Matthew Hitron
Matthew Hitron is a scholar working on Toxicology, Oncology, Molecular Biology, Pulmonary and Respiratory Medicine and Organic Chemistry, having authored 30 papers that have together received 229 indexed citations. Recurring topics across this work include Bioactive Compounds and Antitumor Agents (16 papers), Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (5 papers), HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (3 papers), Cancer Mechanisms and Therapy (3 papers), Acute Myeloid Leukemia Research (3 papers) and Microbial Natural Products and Biosynthesis (3 papers). The work is most often cited by research in Toxicology (60 citations), Oncology (146 citations), Pathology and Forensic Medicine (39 citations), Pharmacology (16 citations) and Cancer Research (21 citations). Matthew Hitron has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Chiang Li, William J. Edenfield, Youzhi Li, Derek J. Jonker, Joe Stephenson, Wěi Li, Adrian Langleben, David Leggett, Jeffrey G. Supko and David Kerstein. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, Pharmacology Research & Perspectives and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.